Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...

In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...

Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...

Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...

Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...

The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a ...

Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...

California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

In his first quarter leading CVS Health, CEO David Joyner laid out the initial steps he’s taking to rightsize the company, as ...